Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.

Mol Oncol · 2022 · PMC8895453 · PMID 34861096

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

While the decrease in cell viability in response to the triple combination was not statistically significantly different from the response to the double combinations, a clear trend was observed, which was confirmed when the Mcl‐1 inhibitor was replaced with the Bcl‐xL inhibitor A‐1331852 (Fig. 5F ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.